NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NVAMD)

Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NVAMD) explained in plain language.

Never miss a new study

Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NVAMD) trials appear

Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NVAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1 Completed 1

New eye injection tested for common causes of vision loss

Disease control Completed

This early-stage study tested a new eye injection called EYE103. It aimed to check its safety and find the best dose for people with vision loss from diabetic macular edema (DME) or 'wet' age-related macular degeneration (NVAMD). For DME, it was tested alone; for NVAMD, it was te…

Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NVAMD)

Phase: PHASE1, PHASE2 • Sponsor: EyeBiotech Ltd. • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NVAMD)

Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NVAMD) trials appear

New eye injection tested for common causes of vision loss